These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29273497)

  • 1. Methotrexate in patients with rheumatoid arthritis in Spain: Subanalysis of the AR Excellence project.
    Tornero-Molina J; Andreu JL; Martín-Martínez MA; Corominas H; Pérez Venegas JJ; Román-Ivorra JA; Sánchez-Alonso F
    Reumatol Clin (Engl Ed); 2019; 15(6):338-342. PubMed ID: 29273497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
    Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
    Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
    Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
    Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort.
    Moura CS; Schieir O; Valois MF; Thorne C; Bartlett SJ; Pope JE; Hitchon CA; Boire G; Haraoui B; Hazlewood GS; Keystone EC; Tin D; Bykerk VP; Bernatsky S;
    Arthritis Care Res (Hoboken); 2020 Aug; 72(8):1104-1111. PubMed ID: 31112011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].
    Nesa L; Gobbi C; Alba P; Exeni I; Babini A; Albiero E
    Rev Fac Cien Med Univ Nac Cordoba; 2007; 64(4):109-14. PubMed ID: 19928400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
    Lau AN; Thorne JC; Movahedi M; Rampakakis E; Cesta A; Li X; Couto S; Sampalis J; Bombardier C;
    J Rheumatol; 2019 Aug; 46(8):874-886. PubMed ID: 30988121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
    Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM
    Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain.
    Alonso A; González CM; Ballina J; García Vivar ML; Gómez-Reino JJ; Marenco JL; Fernández-Nebro A; Ordás C; Cea-Calvo L; Arteaga MJ; Sanmartí R
    Reumatol Clin; 2015; 11(3):144-50. PubMed ID: 25022442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
    Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H; Ohno S; Ishigatsubo Y
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.
    Curtis JR; Zhang J; Xie F; Beukelman T; Chen L; Fernandes J; Ginsberg S; Spettell C; Yun H; Saag KG; Schiff M
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1604-11. PubMed ID: 24942466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration.
    Bianchi G; Caporali R; Todoerti M; Mattana P
    Adv Ther; 2016 Mar; 33(3):369-78. PubMed ID: 26846283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate in rheumatoid arthritis.
    Swierkot J; Szechiński J
    Pharmacol Rep; 2006; 58(4):473-92. PubMed ID: 16963793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.